Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Longitudinal cognitive outcomes in two progressive supranuclear palsy clinical trials.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Trajectories of brain structure and function in young adult carriers of genetic frontotemporal dementia variants.

medRxiv : the preprint server for health sciences·2026
Same author

Clinical Associations of Cerebrospinal Fluid TMEM106B in Familial and Sporadic Frontotemporal Dementia.

JAMA neurology·2026
Same author

Development and validation of a harmonized memory score for multicenter Alzheimer's disease and related dementia research.

Alzheimer's research & therapy·2026
Same author

The BEYONDD Pilot Study: A Decentralized Community-Engaged Research Framework for Multimodal Characterization of Neurodegenerative Risk in a Multi-Ethnic, Midlife Cohort with Subjective Cognitive or Behavioral Complaints.

medRxiv : the preprint server for health sciences·2026
Same author

Remote, self-administered, smartphone cognitive testing in a registry-based cohort: Feasibility, reliability, and validity findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Rowan Saloner1, Joshua Downer2, Argentina Lario Lago3

  • 1Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 24, 2025
PubMed
概括
此摘要是机器生成的。

血液蛋白质学可以在症状出现之前检测出家族前叶退化 (FTLD) 变化. 这项研究使用NULISAseq来识别表达早期FTLD进展的关键血蛋白.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经科学是一个神经科学.
  • 生物标志物 生物标志物
  • 蛋白质组学是指蛋白质组学.

背景情况:

  • 多复合蛋白质组学在阿尔茨海默病研究中提高了精度.
  • 前叶退化 (FTLD) 研究不足利用基于血液的蛋白质组学.
  • 亲属FTLD队列使得研究症状前疾病阶段成为可能.

研究的目的:

  • 识别血液中可检测的蛋白质,这些蛋白质在家族性FTLD中出现症状之前就会发生变化.
  • 使用NUcleic acid链接免疫三明治测试 (NULISAseq) 来发现症状前的FTLD生物标志物.
  • 研究C9orf72,GRN和MAPT突变载体中的早期分子变化.

主要方法:

  • 120名家族FTLD突变携带者和40名对照人接受了血液抽取和临床评估.
  • 使用NULISAseq (132种蛋白质) 进行的向血蛋白质组.
  • 与对照组相比,用于确定蛋白质分歧值的疾病年龄估计;进行了正交测试验证.

主要成果:

  • 在C9orf72 (14种蛋白质),GRN (24种蛋白质) 和MAPT (13种蛋白质) 突变载体和对照体中观察到显著的血蛋白差异.
  • 突触和血管完整性标记物 (NPTX2,NPTXR,PGF) 在症状出现前有所不同.
  • 确定了基因特异性信号 (例如,GRN中的GFAP,MAPT中的C9orf72,FLT1中的ENO2);NULISAseq的目标显示与Simoa和SomaScan一致.

结论:

  • 血蛋白质的改变在预测症状发作之前,在家族性FTLD中可以检测到.
  • 通过与Simoa和SomaScan测试的融合,NULISAseq的目标证明了有效性和大脑相关性.
  • 在更大的队列中进行复制是必要的,以确认临床试验的概括性.